IL-1 pathways in inflammation and human diseases

Nature Reviews Rheumatology

Volumn 6, Issue 4, 2010, Pages 232-241

  Gabay, Cem ^a   Lamacchia, Céline ^a   Palmer, Gaby ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; COLCHICINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMG 108; PLACEBO; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; ANKYLOSING SPONDYLITIS; AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MOLECULAR CLONING; MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAPA SYNDROME; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; PSORIATIC ARTHRITIS; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; COHORT STUDIES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1BETA; MALE; MICE; PROGNOSIS; RECEPTORS, INTERLEUKIN; RHEUMATIC DISEASES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77950627242     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.4     Document Type: Review

References (119)

1. Atkins, e. Pathogenesis of fever. Physiol. Rev. 40, 580-646 (1960).
2. Dinarello, C. A. The interleukin-1 family: 10 years of discovery. FASEB J. 8, 1314-1325 (1994).
3. Auron, P. e. et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl Acad. Sci. USA 81, 7907-7911 (1984). (Pubitemid 15169171)
4. March, C. J. et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315, 641-647 (1985).
5. webb, A. C. et al. Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res. 5, 77-85 (1986). (Pubitemid 16004493)
6. Bensi, G. et al. Human interleukin-1 beta gene. Gene 52, 95-101 (1987). (Pubitemid 17076153)
7. Priestle, J. P., Schär, H. P. & Grütter, M. G. Crystallographic refinement of interleukin 1 beta at 2.0 A resolution. Proc. Natl Acad. Sci. USA 86, 9667-9671 (1989).
8. Graves, B. J. et al. Structure of interleukin 1 alpha at 2.7-A resolution. Biochemistry 29, 2679-2684 (1990).
9. Stevenson, F. T., Bursten, S. L., Fanton, C., Locksley, R. M. & Lovett, D. H. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc. Natl Acad. Sci. USA 90, 7245-7249 (1993). (Pubitemid 23222426)
10. Carruth, L. M., Demczuk, S. & Mizel, S. B. Involvement of a calpain-like protease in the processing of the murine interleukin 1α precursor. J. Biol. Chem. 266, 12162-12167 (1991). (Pubitemid 21907072)
11. Jacques, C., Gosset, M., Berenbaum, F. & Gabay, C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam. Horm. 74, 371-403 (2006).
12. Mosley, B. et al. The interleukin-1 receptor binds the human interleukin-1α precursor but not the interleukin-1β precursor. J. Biol. Chem. 262, 2941-2944 (1987). (Pubitemid 17127537)
13. Black, R. A. et al. Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J. Biol. Chem. 263, 9437-9442 (1988).
14. Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356, 768-774 (1992).
15. Franchi, L., eigenbrod, T., Muñoz-Planillo, R. & Nunez, G. The inflammasome: a caspase-1- activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241-247 (2009).
16. Lamkanfi, M. & Dixit, v. M. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227, 95-105 (2009).
17. Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
18. Allen, I. C. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30, 556-565 (2009).
19. Thomas, P. G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566-575 (2009).
20. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178 (2009).
21. Arend, w. P., Palmer, G. & Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20-38 (2008). (Pubitemid 351986169)
22. Netea, M. G. et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 113, 2324-2335 (2009).
23. Keller, M., Ruegg, A., werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831 (2008). (Pubitemid 351312798)
24. Fantuzzi, G. & Dinarello, C. A. Interleukin-18 and interleukin-1β: two cytokine substrates for ICe (caspase-1). J. Clin. Immunol. 19, 1-11 (1999). (Pubitemid 29113328)
25. Greten, F. R. et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 130, 918-931 (2007).
26. Guma, M. et al. Caspase 1-independent activation of interleukin-1beta in neutrophilpredominant inflammation. Arthritis Rheum. 60, 3642-3650 (2009).
27. Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum. 60, 3651-3662 (2009).
28. Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009).
29. Gu, Y. et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275, 206-209 (1997). (Pubitemid 27034760)
30. Talabot-Ayer, D., Lamacchia, C., Gabay, C. & Palmer, G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J. Biol. Chem. 284, 19420-19426 (2009).
31. Sims, J. e. et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 241, 585-589 (1988).
32. Dunne, A. & O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE 2003, re3 (2003).
33. Boraschi, D. & Tagliabue, A. The interleukin-1 receptor family. Vitam. Horm. 74, 229-254 (2006).
34. Greenfeder, S. A. et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J. Biol. Chem. 270, 13757-13765 (1995).
35. Miller, L. S. et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 24, 79-91 (2006).
36. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147 (1996).
37. Chung, Y. et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30, 576-587 (2009).
38. Acosta-Rodriguez, e. v., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007). (Pubitemid 47300008)
39. Arend, w. P., Joslin, F. G. & Massoni, R. J. effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J. Immunol. 134, 3868-3875 (1985). (Pubitemid 15073522)
40. Balavoine, J. F. et al. Prostaglandin e2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78, 1120-1124 (1986). (Pubitemid 17177097)
41. Arend, w. P., welgus, H. G., Thompson, R. C. & eisenberg, S. P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85, 1694-1697 (1990). (Pubitemid 20176469)
42. Fischer, e. et al. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am. J. Physiol. 261, R442-R452 (1991).
43. Gabay, C. & Palmer, G. Mutations in the IL-1RN locus lead to autoinflammation. Nat. Rev. Rheumatol. 9, 480-482 (2009).
44. Sims, J. e., Giri, J. G. & Dower, S. K. The two interleukin-1 receptors play different roles in IL-1 actions. Clin. Immunol. Immunopathol. 72, 9-14 (1994).
45. Colotta, F., Dower, S. K., Sims, J. e. & Mantovani, A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol. Today 15, 562-566 (1994). (Pubitemid 24353906)
46. Garlanda, C., Anders, H. J. & Mantovani, A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 30, 439-446 (2009).
47. Jensen, L. e., Muzio, M., Mantovani, A. & whitehead, A. S. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. 164, 5277-5286 (2000). (Pubitemid 30305206)
48. Smith, D. E. et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18, 87-96 (2003).
49. Smith, D. E. et al. A central nervous systemrestricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1. Immunity 30, 817-831 (2009).
50. Burns, K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263-268 (2003). (Pubitemid 36152320)
51. Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191-202 (2002). (Pubitemid 34876547)
52. Finckh, A. & Gabay, C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr. Opin. Rheumatol. 20, 269-275 (2008). (Pubitemid 351483315)
53. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196-2204 (1998). (Pubitemid 29009378)
54. Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 46, 614-624 (2002). (Pubitemid 34214243)
55. Jiang, Y. et al. A multicenter, double-blind, doseranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000). (Pubitemid 30368176)
56. Genovese, M. C. et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412-1419 (2004).
57. Alten, R. et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R67 (2008). (Pubitemid 351903406)
58. Bensen, w. G. et al. Results of a phase 2 randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R type I) in patients with rheumatoid arthritis [abstract #994]. Arthritis Rheum. 58 (Suppl.), S535 (2008).
59. Drevlow, B. e. et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39, 257-265 (1996). (Pubitemid 26069676)
60. Pavelka, K. et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICe) inhibitor, in a 285 patient Phase II trial in rheumatoid arthritis [abstract LB02]. Arthritis Rheum. 46, 3415 (2002).
61. Agostini, L. et al. NLRP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-wells autoinflammatory disorder. Immunity 20, 319-325 (2004). (Pubitemid 38388233)
62. Hoffman, H. M. et al. Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004).
63. Hawkins, P. N., Lachmann, H. J. & McDermott, M. F. Interleukin-1-receptor antagonist in the Muckle-wells syndrome. N. Engl. J. Med. 348, 2583-2584 (2003).
64. Hoffman, H. M. et al. efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
65. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
66. Aksentijevich, I. et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360, 2426-2437 (2009).
67. Reddy, S. et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360, 2438-2444 (2009).
68. Chae, J. J. et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 112, 1794 - 1803 (2008).
69. Chae, J. J. et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11, 591-604 (2003).
70. Chae, J. J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl Acad. Sci. USA 103, 9982-9987 (2006).
71. Yu, J. w. et al. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 13, 236-249 (2006).
72. Seshadri, S., Duncan, M. D., Hart, J. M., Gavrilin, M. A. & wewers, M. D. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J. Immunol. 179, 1274-1281 (2007).
73. Roldan, R., Ruiz, A. M., Miranda, M. D. & Collantes, e. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75, 504-505 (2008).
74. Shoham, N. G. et al. Pyrin binds the PSTPIP1/ CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501-13506 (2003).
75. Yu, J. w. et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 28, 214-227 (2007).
76. Dierselhuis, M. P., Frenkel, J., wulffraat, N. M. & Boelens, J. J. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44, 406-408 (2005). (Pubitemid 40361307)
77. Mandey, S. H., Kuijk, L. M., Frenkel, J. & waterham, H. R. A role for geranylgeranylation in interleukin-1β secretion. Arthritis Rheum. 54, 3690-3695 (2006).
78. Kuijk, L. M. et al. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/ PKB-dependent caspase-1 activation. Blood 112, 3563-3573 (2008).
79. Cailliez, M. et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29, 763 (2006).
80. Lobito, A. A. et al. Abnormal disulfide-linked oligomerization results in eR retention and altered signaling by TNFR1 mutants in TNFR1- associated periodic fever syndrome (TRAPS). Blood 108, 1320-1327 (2006).
81. Todd, I. et al. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum. 56, 2765-2773 (2007). (Pubitemid 47237296)
82. Gattorno, M. et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptorassociated periodic syndrome. Arthritis Rheum. 58, 1516-1520 (2008). (Pubitemid 351705941)
83. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
84. Martin, T. M. et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum. 60, 611-618 (2009).
85. de Koning, H. D. et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis Rheum. 37, 137-148 (2007).
86. Pascual, v., Allantaz, F., Arce, e., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005). (Pubitemid 40664091)
87. Gattorno, M. et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58, 1505-1515 (2008). (Pubitemid 351705940)
88. Ruperto, N. et al. A phase II trial with Canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA) [abstract #OP-0298]. Ann. Rheum. Dis. 68 (Suppl. 3), 170 (2009).
89. Kelly, A. & Ramanan, A. v. A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4, 615-620 (2008).
90. Lequerre, T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67, 302-308 (2008). (Pubitemid 351281262)
91. Martinon, F., Petrilli, v., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
92. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007). (Pubitemid 46511126)
93. Announ, N., Palmer, G., Guerne, P. A. & Gabay, C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76, 424-426 (2009).
94. Terkeltaub, R. et al. Placebo-controlled pilot study of Rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis [abstract LB518-L2]. Arthritis Rheum. 56, 4231-4232 (2007).
95. Picco, P. et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1β receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 60, 264-268 (2009).
96. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
97. Lust, J. A. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84, 114-122 (2009).
98. Merhi-Soussi, F. et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein e-knockout mice. Cardiovasc. Res. 66, 583-593 (2005). (Pubitemid 40725770)
99. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, w. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39, 797-809 (1996). (Pubitemid 26140426)
100. Arner, e. C., Harris, R. R., DiMeo, T. M., Collins, R. C. & Galbraith, w. Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit. J. Rheumatol. 22, 1338-1346 (1995).
101. van Lent, P. L. et al. Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice. J. Rheumatol. 22, 2250-2258 (1995).
102. Kuiper, S. et al. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10, 690-702 (1998). (Pubitemid 28457113)
103. Ma, Y. et al. Altered susceptibility to collageninduced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum. 41, 1798 - 1805 (1998). (Pubitemid 28465533)
104. Palmer, G. et al. Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis. Eur. J. Immunol. 33, 434-440 (2003). (Pubitemid 36267608)
105. Bakker, A. C. et al. Prevention of murine collageninduced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum. 40, 893-900 (1997).
106. Nguyen, K. H. et al. Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis. J. Rheumatol. 25, 1118-1125 (1998).
107. Pan, R. Y. et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum. 43, 289-297 (2000).
108. Oligino, T. J., Ghivizzani, S. & wolfe, D. Intraarticular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther. 6, 1713-1720 (1996). (Pubitemid 29485946)
109. Otani, K. et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J. Immunol. 156, 3558-3562 (1996). (Pubitemid 26123574)
110. Muller-Ladner, U. et al. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. J. Immunol. 158, 3492-3498 (1997). (Pubitemid 127484071)
111. economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52 (2003).
112. van den Berg, w. B., Joosten, L. A., Helsen, M. & van de Loo, F. A. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237-243 (1994). (Pubitemid 24207133)
113. Choe, J. Y., Crain, B., wu, S. R. & Corr, M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by tolllike receptor 4 signaling. J. Exp. Med. 197, 537-542 (2003). (Pubitemid 36278608)
114. Schorlemmer, H. U., Kanzy, e. J., Langner, K. D. & Kurrle, R. Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis. Agents Actions 39, C113-C116 (1993). (Pubitemid 23276744)
115. Dawson, J. et al. effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 38, 401-406 (1999). (Pubitemid 29507122)
116. Bessis, N. et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur. J. Immunol. 30, 867-875 (2000). (Pubitemid 30216260)
117. Smeets, R. L. et al. Soluble interleukin-1 receptor accessory protein ameliorates collageninduced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum. 52, 2202-2211 (2005).
118. Smeets, R. L. et al. effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum. 48, 2949-2958 (2003). (Pubitemid 37280625)
119. Ku, G., Faust, T., Lauffer, L. L., Livingston, D. J. & Harding, M. w. Interleukin-1β converting enzyme inhibition blocks progression of type II collageninduced arthritis in mice. Cytokine 8, 377-386 (1996). (Pubitemid 26164713)